Charles River Laboratories Announces Second-Quarter 2024 Results
Charles River Laboratories Announces Second-Quarter 2024 Results | Charles River Laboratories International, Inc. Charles River provides essential products and services to help …
Investor Relations - Charles River Laboratories International, Inc.
May 11, 2023 · WILMINGTON, Mass. -- (BUSINESS WIRE)--May 11, 2023-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of …
Charles River Laboratories Plans to Increase CRADL Capacity in ...
To further support the Cambridge biohub, Charles River is expanding locally, including the second phase of its multi-year expansion program that begun in 2021, increasing capacity for contract breeding and housing of genetically modified colonies in Wilmington, Massachusetts.
Investor Relations - Charles River Laboratories International, Inc.
Dec 31, 2020 · The acquisition of Distributed Bio expands Charles River’s scientific capabilities with an innovative, large-molecule discovery platform. The transaction combines Distributed Bio’s antibody libraries and immuno-engineering platform with Charles River’s extensive drug discovery and non-clinical development expertise to create an integrated ...
Charles River Laboratories Announces Third-Quarter 2024 Results
Nov 6, 2024 · Revenue for the RMS segment was $197.8 million in the third quarter of 2024, an increase of 5.9% from $186.8 million in the third quarter of 2023. The Noveprim acquisition in November 2023 contributed 4.9% to third-quarter RMS reported revenue, and the impact of foreign currency translation increased revenue by 0.4%.
Investor Relations - Charles River Laboratories International, Inc.
Feb 16, 2022 · Revenue for the DSA segment was $534.1 million in the fourth quarter of 2021, an increase of 7.9% from $495.0 million in the fourth quarter of 2020. The impact of foreign currency translation reduced revenue by 0.4%, and acquisitions contributed 1.6% to DSA revenue growth.
Charles River Laboratories Announces Third-Quarter 2023 Results
Nov 8, 2023 · WILMINGTON, Mass. -- (BUSINESS WIRE)--Nov. 8, 2023-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 3.8% from $989.2 million in the third quarter of 2022.
Investor Relations - Charles River Laboratories International, Inc.
WILMINGTON, Mass. -- (BUSINESS WIRE)--Mar. 12, 2024-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 26 th Annual Global Healthcare Conference on Wednesday, March 13 th, at 10:15 a.m. ET. Management will present an overview of Charles River’s strategic focus, business ...
Charles River Announces Rare Disease Gene Therapy Collaboration …
Apr 9, 2024 · Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
Feb 14, 2024 · On November 30, 2023, Charles River Laboratories completed the acquisition of an additional 41% equity stake of Noveprim Group, a Mauritius-based provider of non-human primates (NHPs) for regulatory required biomedical, …